Biotechnology: analysis of 14 November 2026
Back to the Chronology · Current news in this section

Analysis
GLP-1 obesity drugs dominated the week, with the FDA warning of a rare vision-loss risk even as Lilly won China's first oral GLP-1 approval and Blackstone committed $1.5bn to Pfizer's monthly shot.
The GLP-1 class remained the centre of gravity for biotechnology news, combining regulatory caution with commercial expansion: the FDA flagged a small and contested risk of a rare condition causing vision loss 123, while reports highlighted widespread off-label and modified use driven by cost and access barriers 4, and Lilly's orforglipron became China's first approved oral GLP-1 for obesity 16. Capital flowed in unusual ways, with private equity underwriting Pfizer's Phase 3 obesity programme 2021, neurology start-ups raising around $450m 11, and Windward pricing a $175m IPO built on China-licensed assets 15. Policy and geopolitics loomed in the background, from US 'most-favoured nations' pricing pressure 2930 and FDA staffing shortages 24 to BIO's call for a national biotechnology strategy against Chinese competition 14 and a reported Chinese plan to restrict biotech exports 41. On the science side, Google DeepMind's AlphaGenome 2 25, a pharmacogenomic analysis of the All of Us cohort 18 and a 30-year review of AAV gene therapy submissions pointed to the growing role of large datasets and AI in drug development.
Key developments
- FDA flags rare vision-loss risk with GLP-1s. The FDA warned that GLP-1 drugs may carry a small risk of a rare condition causing vision loss, while acknowledging that the data are mixed [1]. Commentators argued that even uncommon complications matter when a drug is taken by millions [23], and the warning lands as reports show many Americans modifying doses or using unapproved versions because of cost and access barriers [4], which could complicate safety monitoring. 1423
- Lilly wins China's first oral GLP-1 obesity approval. China's National Medical Products Administration approved Lilly's orforglipron, making it the country's first available oral GLP-1 for obesity and giving Lilly a head start over Novo Nordisk in a large market [16]. The approval comes as Lilly's relationships with telehealth firms marketing GLP-1s draw conflict-of-interest scrutiny following Oura's acquisition of a health tech start-up [12], and celebrity testimonials such as DJ Khaled's reported 90-pound loss keep consumer demand high [7]. 16127
- Blackstone funds Pfizer's monthly obesity shot. Blackstone is committing $1.5bn to support the Phase 3 programme for a monthly GLP-1 injection Pfizer acquired by winning a bidding war for Metsera, a deal reported at up to $10bn [20][21]. Private equity financing of late-stage pharma trials is a notable structure, reflecting both the cost of competing in obesity and investors' appetite for the category. 2021
- Capital returns to neurology and China-sourced assets. Five neurology start-ups raised around $450m in recent weeks, while investors reacted coolly to new cell therapy data [11]. Swiss biotech Windward priced a $175m IPO to advance two China-licensed lung drugs it hopes can rival AstraZeneca and Amgen's Tezspire [15], and PepGen's shares jumped on early muscular dystrophy data that the company says compares favourably with rivals at Novartis and Dyne [2]; Silence was acquired for $1.3bn [38] and Novo filed a sickle cell drug it views as a future blockbuster [10]. 111523810
- Pricing policy and FDA staffing strain the industry. Drugmakers are reportedly rethinking launches abroad to protect US sales from the 'most-favoured nations' policy [29], and a study suggested German price rises could push US costs higher amid tensions that have led some companies to scale back German investment [30]. Separately, the FDA has more than 1,000 open jobs after last year's staff exodus, with knock-on effects for sponsors' timelines [24]. 293024
- AI and big data reshape genomics research. Google DeepMind released AlphaGenome 2, which analyses genetic variants at single-cell-type resolution and reportedly identifies nearly twice as many disease-relevant changes as its predecessor [25], while a former ByteDance scientist's venture claimed its NovaAtom-Lite model outperforms state-of-the-art systems [28]. A study of nearly 100,000 All of Us participants found everyone carried at least one drug-affecting variant and a quarter had been prescribed a medication affected by it [18], underscoring the clinical relevance of such tools. 25281833
Themes
- GLP-1 boom brings regulatory and governance scrutiny. Rapid uptake, new approvals and large financings sit alongside safety warnings, off-label use and questions about the independence of GLP-1 marketing channels. The class is now large enough that rare risks and commercial conflicts have population-scale consequences. 14121620
- Biotech as a US-China strategic contest. BIO urged Washington to adopt a national biotechnology strategy to counter China's gains [14], while China is reported to be planning restrictions on biotech exports [41]. At the same time, Western companies continue to license Chinese assets [15] and seek Chinese approvals [16], highlighting the interdependence beneath the rivalry. 14411516
- Alternatives to animal models and traditional screening. Araceli raised $4.5m for human-cell imaging tools meant to reduce animal testing [5], DeepMind and others are pushing AI variant and structure prediction [25][28], and Nature Biotechnology papers covered de novo protease design and RNA-fingerprint perturbation searches [36][39]. Together they signal a shift toward computational and human-cell-based discovery. 525283639
What to watch
- Whether the FDA's vision-loss warning prompts label changes or further studies, and how it interacts with widespread modified and unapproved GLP-1 use. 1423
- Biogen's imminent pivotal lupus readout, which could reset expectations for a company seeking new growth drivers. 27
- Alnylam's response to slowing Amvuttra sales and Bristol Myers' R&D restructuring following its research chief's departure. 2622
- Developments on China's planned biotech export ban and US pricing policy, which could reshape cross-border licensing and launch strategies. 41293014
Stories this analysis is based on (28)
- FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss Ars Technica
- PepGen soars on promising early data for muscular dystrophy drug BioPharma Dive
- Millions of Americans are not taking their GLP-1 drugs as prescribed Ars Technica
- Araceli raises $4.5M for drug discovery tools aimed at reducing animal testing GeekWire Startups
- DJ Khaled shares he lost 90 pounds with help of GLP-1 drug The Hill
- Novo submits sickle cell drug; Flagship, Gates Foundation deepen ties BioPharma Dive
- This week in charts: Brain drugs are back on venture’s minds BioPharma Dive
- STAT+: Oura’s acquisition of health tech startup raises conflict-of-interest questions for Eli Lilly, experts say STAT Biotech
- China’s demographic challenge becoming its biotech advantage Asia Times
- Windward prices $175M IPO to advance China-licensed lung drugs BioPharma Dive
- Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug South China Morning Post
- High Frequency of Drug-Impacting Gene Variants Found in All of Us Cohort GEN (Genetic Engineering & Biotechnology News)
- Blackstone bets $1.5B on Pfizer’s obesity drug BioPharma Dive
- STAT+: Blackstone backs Pfizer’s bet on monthly obesity treatment STAT Biotech
- Bristol Myers research chief to depart in ‘evolution’ of company’s structure BioPharma Dive
- The risk of blindness from GLP-1 drugs is too serious to ignore The Hill
- The FDA has over 1k open jobs — and the staffing shortage is hitting pharma BioPharma Dive
- Google Deepmind shifts genomics AI from bulk tissue predictions to single cell type resolution with AlphaGenome 2 The Decoder
- STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem STAT Biotech
- STAT+: What to know about Biogen’s big lupus study readout STAT Biotech
- Former ByteDance AI scientist touts drug-discovery model that tops world leaders South China Morning Post
- STAT+: Most-favored nations policy makes drugmakers rethink launches abroad STAT Biotech
- Drug price hikes in Germany could push US costs higher, study says BioPharma Dive
- Binding Mode Matters: Hotspot-Aware Drug Discovery via Explorative Preferences arXiv (research papers)
- De novo design of proteases Nature Biotechnology
- Silence snapped up for $1.3 billion Nature Biotechnology
- Searching perturbation dictionaries with RNA fingerprints Nature Biotechnology
- China plans ban on biotech exports Nature Biotechnology
Written by Claude Fable 5.1 (Anthropic), based on 45 recent headlines and excerpts in this section, 6d ago. AI analysis can misread or miss things: the numbers link to the original reporting, which is the authority.